FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 313:656-659 September 12, 1985 Number 11 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

To evaluate the long-term effects of dopamine agonists in the treatment of macroprolactinoma, we studied prolactin levels and tumor size for 30 to 88 months (57 +/- 14, mean +/- S.D.) in 38 patients treated with bromocriptine or lisuride. Elevated prolactin levels became normal in 30 patients, and the tumor shrank in 29. After two years of treatment, we attempted to reduce the maintenance dose (5 to 20 mg of bromocriptine per day or 0.4 to 0.8 mg of lisuride per day); in 21 patients no changes in prolactin levels or tumor size were observed over 6 to 52 months with 0.625 to 10 mg of bromocriptine per day or 0.05 mg of lisuride per day. However, it was possible to withdraw the drug in only one patient. We conclude that dopamine agonists are usually effective treatments for macroprolactinoma and that after a response has been obtained, it can be maintained in many patients with a greatly reduced dose.

This article has been cited by other articles:

• Schlechte, J. A. (2007). Long-Term Management of Prolactinomas. J. Clin. Endocrinol. Metab. 92: 2861-2865 [Abstract] [Full Text]  
• Gurlek, A., Karavitaki, N., Ansorge, O., Wass, J. A H (2007). What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics. Eur J Endocrinol 156: 143-153 [Abstract] [Full Text]  
• Gillam, M. P., Molitch, M. E., Lombardi, G., Colao, A. (2006). Advances in the Treatment of Prolactinomas. Endocr. Rev. 27: 485-534 [Abstract] [Full Text]  
• Talkad, A. V., Kattah, J. C., Xu, M. Y., Orth, E. H., Chang, J. Y. (2004). Prolactinoma presenting as painful postganglionic Horner syndrome. Neurology 62: 1440-1441 [Full Text]  
• Schlechte, J. A. (2003). Prolactinoma. NEJM 349: 2035-2041 [Full Text]  
• Freda, P. U., Andreadis, C. I., Khandji, A. G., Khoury, M., Bruce, J. N., Jacobs, T. P., Wardlaw, S. L. (2000). Long-Term Treatment of Prolactin-Secreting Macroadenomas with Pergolide. J. Clin. Endocrinol. Metab. 85: 8-13 [Full Text]  
• DRANGE, M. R., FRAM, N. R., HERMAN-BONERT, V., MELMED, S. (2000). Pituitary Tumor Registry: A Novel Clinical Resource. J. Clin. Endocrinol. Metab. 85: 168-174 [Abstract] [Full Text]  
• Colao, A., Di Sarno, A., Landi, M. L., Cirillo, S., Sarnacchiaro, F., Facciolli, G., Pivonello, R., Cataldi, M., Merola, B., Annunziato, L., Lombardi, G. (1997). Long-Term and Low-Dose Treatment with Cabergoline Induces Macroprolactinoma Shrinkage. J. Clin. Endocrinol. Metab. 82: 3574-3579 [Abstract] [Full Text]  
• Tyson, D., Reggiardo, D., Sklar, C., David, R. (1993). Prolactin-Secreting Macroadenomas in Adolescents: Response to Bromocriptine Therapy. Arch Pediatr Adolesc Med 147: 1057-1061 [Abstract]  
• Vance, M. L., Lipper, M., Klibanski, A., Biller, B. M. K., Samaan, N. A., Molitch, M. E. (1990). Treatment of Prolactin-Secreting Pituitary Macroadenomas with the Long-acting Non-Ergot Dopamine Agonist CV 205-502. ANN INTERN MED 112: 668-673 [Abstract]